Co-founder and Chief Medical Officer, MDisrupt

Jill is a board-certified pathologist with subspecialty boards in molecular genetic pathology and a fellowship in pathology/oncology informatics. Jill’s expertise is in health product strategy, coding/coverage/reimbursement, medical and regulatory affairs, health policy, clinical laboratory medicine, molecular diagnostics, population health, provider education, patient engagement, and medical diligence for health tech.

Building on this expertise with her latest venture, MDisrupt is providing medical diligence for the health tech industry, to help ensure wiser investments and to illuminate a clear path and timeline to widespread market adoption of novel health tech products. 

Jill serves on a number of medical professional societies as an active member in the Association for Molecular Pathology, the College of American Pathologists, American College of Medical Genetics and Genomics, and the National Academies of Science, Engineering, and Medicine’s Roundtable on Genomics and Precision Health.

Jill received her Medical Degree from Stanford University School of Medicine, did residency training at the University of California at San Francisco and the University of Iowa, and completed fellowships at the University of Pittsburgh Medical Center. Subsequently, she practiced pathology at Creighton University Medical Center where she founded iKaryos Diagnostics. Jill previously was the Chief Medical Officer at Color Genomics, 23andMe, Invitae, and Complete Genomics.